FDA conducts safety review of antihypertensive ARB olmesartan
Links shared publicly online about this topic.
- 1,094total visits
FDA conducts safety review of antihypertensive ARB olmesartan
There were cautionary signals in two placebo-controlled hypertension trials; still, the agency says, it believes the benefits of the drug, marketed by Daiichi Sankyo as Benicar,
View full resource at theheart.org
Tags: Heart Disease, High Blood Pressure, High Blood Pressure Medication, Drug, FDA, Benicar, Olmetec, Daiichi Sankyo
Most Recently Shared on June 14, 2010 at 4:30 pm By:
FDA reviews olmesartan safety record, cites CV deaths in trials: There were cautionary signals in two placebo-cont... http://bit.ly/9MjGEh
Advertisement
